NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients

Oncotarget
Victor PallarèsRamon Mangues

Abstract

Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this subgroup to implement risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein family regulates cell proliferation, survival, migration and adhesion. Despite its association with metastatic dissemination and prognosis of different solid tumors, the role of these proteins in hematological malignancies has been scarcely evaluated. Nevertheless, previous work has established an important role for the CAS family members NEDD9 or BCAR1 in the migratory and dissemination capacities of myeloid cells. On this basis, we hypothesized that NEDD9 or BCAR1 expression levels could associate with survival in IR-AML patients and become new prognostic markers. To that purpose, we assessed BCAR1 and NEDD9 gene expression in a cohort of 73 adult AML patients validating the results in an independent cohort (n = 206). We have identified NEDD9, but not BCAR1, as a new a marker for longer overall and disease-free survival, and for lower ...Continue Reading

References

Jan 24, 1998·The Journal of Biological Chemistry·R de JongJ Groffen
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Sep 9, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sachiko SeoHisamaru Hirai
Nov 11, 2005·Leukemia·G PereaUNKNOWN Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel
Oct 3, 2007·Cancer Research·Geraldine M O'NeillErica A Golemis
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
May 10, 2008·Journal of Cellular Biochemistry·Tetsuya NakamotoSeiichi Kitagawa
Dec 2, 2008·Leukemia Research·Emmanuelle Tavernier-TardyDenis Guyotat
Sep 10, 2009·Cancer Research·Eugene IzumchenkoErica A Golemis
Nov 26, 2009·Cellular and Molecular Life Sciences : CMLS·Nadezhda TikhmyanovaErica A Golemis
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claire L GreenRosemary E Gale
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Feb 5, 2013·Blood·Marta PratcoronaUNKNOWN Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas
Jun 26, 2014·IUBMB Life·Anna S NikonovaErica A Golemis
Feb 20, 2015·Hematology·Konstanze Döhner, Peter Paschka
Jun 27, 2015·Seminars in Hematology·Andreas ReinischRavindra Majeti
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Sep 29, 2015·Archives of Pathology & Laboratory Medicine·Michael L Wang, Nathanael G Bailey
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell

❮ Previous
Next ❯

Citations

Dec 14, 2018·Biomolecules·Cigdem Usul AfsarFaruk Tas
Aug 15, 2019·Cancer Biotherapy & Radiopharmaceuticals·Luowen WangXuan Yang
Aug 26, 2021·Journal of Cellular and Molecular Medicine·Shenghao HuaXuejun Shao

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
Assay

Software Mentioned

R Foundation for Statistical Computing
R Studio
SPSS
R
cmprsk

Related Concepts

Related Feeds

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Aphasia

Aphasia affects the ability to process language, including formulation and comprehension of language and speech, as well as the ability to read or write. Here is the latest research on aphasia.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.